

Michael Allison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8941613/publications.pdf>

Version: 2024-02-01

42
papers

4,853
citations

218592

26
h-index

289141

40
g-index

46
all docs

46
docs citations

46
times ranked

5995
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	2.6	20
2	Risk for arterial thrombosis after liver transplantation with hepatic artery reconstruction. BJS Open, 2022, 6, .	0.7	0
3	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	1.8	54
4	Liver Transplantation Outcomes From Controlled Circulatory Death Donors. Annals of Surgery, 2022, 275, 1156-1164.	2.1	61
5	Transcriptional, epigenetic and metabolic signatures in cardiometabolic syndrome defined by extreme phenotypes. Clinical Epigenetics, 2022, 14, 39.	1.8	6
6	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100477.	2.6	31
7	Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma. Hepatology, 2021, 73, 1028-1044.	3.6	76
8	Psychosocial Evaluation of Candidates for Solid Organ Transplantation. Transplantation, 2021, 105, e292-e302.	0.5	10
9	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 185-198.	3.7	130
10	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
11	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. Lancet, The, 2021, 397, 1770-1780.	6.3	18
12	The Liver Retransplantation Risk Score: a prognostic model for survival after adult liver retransplantation. Transplant International, 2021, 34, 1928-1937.	0.8	9
13	P091â€¦A coordinated national response maintained a safe and effective UK liver transplant program during the first year of the COVID-19 pandemic. , 2021, , .		0
14	Î²2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development. Science Translational Medicine, 2021, 13, eabk2267.	5.8	23
15	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. Lancet, The, 2020, 395, 226-239.	6.3	53
16	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	0.8	71
17	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine, 2020, 12, .	5.8	205
18	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compoundâ€”Toward Improved Detection of Liver Impairment. Clinical and Translational Gastroenterology, 2020, 11, e00239.	1.3	34

#	ARTICLE	IF	CITATIONS
19	Bile Biochemistry Following Liver Reperfusion in the Recipient and Its Association With Cholangiopathy. <i>Liver Transplantation</i> , 2020, 26, 1000-1009.	1.3	16
20	Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1899-1912.	0.6	157
21	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	3.7	411
22	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	1.8	279
23	ACG Clinical Guideline for Alcoholic Liver Disease: The MELD Threshold for Corticosteroid Treatment has Yet to be Established. <i>American Journal of Gastroenterology</i> , 2019, 114, 175-176.	0.2	6
24	Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients. <i>Liver International</i> , 2019, 39, 353-360.	1.9	11
25	Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 442-453.	1.9	48
26	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	0.6	777
27	Reply to: "The long-term prognosis of alcoholic hepatitis is poor and independent of disease severity for patients surviving an acute episode". <i>Journal of Hepatology</i> , 2018, 68, 1332.	1.8	0
28	Observations on the ex situ perfusion of livers for transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2005-2020.	2.6	260
29	Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 511-518.	1.8	73
30	Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption. <i>Genome Biology</i> , 2018, 19, 79.	3.8	83
31	Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 1200-1201.	1.8	21
32	The impact of rifaximin on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). <i>Frontline Gastroenterology</i> , 2017, 8, 243-251.	0.9	26
33	26-hour Storage of a Declined Liver Before Successful Transplantation Using Ex Vivo Normothermic Perfusion. <i>Annals of Surgery</i> , 2017, 265, e1-e2.	2.1	42
34	In Patients With Severe Alcoholic Hepatitis, Prednisolone Increases Susceptibility to Infection and Infection-Related Mortality, and Is Associated With High Circulating Levels of Bacterial DNA. <i>Gastroenterology</i> , 2017, 152, 1068-1077.e4.	0.6	141
35	Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 65, 1165-1180.	3.6	138
36	Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. <i>Journal of Hepatology</i> , 2015, 63, 1139-1146.	1.8	110

#	ARTICLE	IF	CITATIONS
37	Prednisolone or Pentoxifylline for Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2015, 372, 1619-1628.	13.9	602
38	Fatty Acid and Glucose Sensors in Hepatic Lipid Metabolism: Implications in NAFLD. <i>Seminars in Liver Disease</i> , 2015, 35, 250-261.	1.8	46
39	Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0140312.	1.1	11
40	The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2x2 factorial randomised controlled trial. <i>Health Technology Assessment</i> , 2015, 19, 1-104.	1.3	34
41	Successful surgical management of ruptured umbilical hernias in cirrhotic patients. <i>World Journal of Gastroenterology</i> , 2015, 21, 3109.	1.4	45
42	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <i>Cell Cycle</i> , 2014, 13, 1489-1494.	1.3	54